- Home
- SCPH vs GNLX Comparison
SCPH vs GNLX Comparison
Compare SCPH & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- GNLX
- Stock Information
- Founded
- SCPH 2013
- GNLX 2001
- Country
- SCPH United States
- GNLX United States
- Employees
- SCPH N/A
- GNLX N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- GNLX Health Care
- Exchange
- SCPH Nasdaq
- GNLX Nasdaq
- Market Cap
- SCPH 173.6M
- GNLX 184.4M
- IPO Year
- SCPH 2017
- GNLX 2023
- Fundamental
- Price
- SCPH $3.25
- GNLX $4.81
- Analyst Decision
- SCPH Strong Buy
- GNLX Strong Buy
- Analyst Count
- SCPH 2
- GNLX 4
- Target Price
- SCPH $15.00
- GNLX $18.25
- AVG Volume (30 Days)
- SCPH 267.8K
- GNLX 331.4K
- Earning Date
- SCPH 03-12-2025
- GNLX 03-31-2025
- Dividend Yield
- SCPH N/A
- GNLX N/A
- EPS Growth
- SCPH N/A
- GNLX N/A
- EPS
- SCPH N/A
- GNLX N/A
- Revenue
- SCPH $30,278,000.00
- GNLX $8,000.00
- Revenue This Year
- SCPH $172.27
- GNLX N/A
- Revenue Next Year
- SCPH $131.75
- GNLX N/A
- P/E Ratio
- SCPH N/A
- GNLX N/A
- Revenue Growth
- SCPH 303.87
- GNLX N/A
- 52 Week Low
- SCPH $3.08
- GNLX $1.60
- 52 Week High
- SCPH $6.54
- GNLX $8.67
- Technical
- Relative Strength Index (RSI)
- SCPH 43.27
- GNLX 58.52
- Support Level
- SCPH $3.09
- GNLX $4.62
- Resistance Level
- SCPH $3.87
- GNLX $5.76
- Average True Range (ATR)
- SCPH 0.20
- GNLX 0.57
- MACD
- SCPH 0.00
- GNLX -0.03
- Stochastic Oscillator
- SCPH 20.65
- GNLX 59.96
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.